Abstract:Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all, human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms: mutation of the gene leading to an absence of tumour suppressor activity and, in some cases, gain-of-oncogenic function; or inhibition of the wild-type p53 protein mediated by overexpression of its negative regulators MDM2 and MDMX. Because of its high potency as a tumour suppressor and the dependence of at least some established tumours on its inactivation, p53 appears to be a highly attractive target for the development of new anticancer drugs. However, p53 is a transcription factor and therefore has long been considered undruggable. Nevertheless, several innovative strategies have been pursued for targeting dysfunctional p53 for cancer treatment. In mutant p53-expressing tumours, the predominant strategy is to restore tumour suppressor function with compounds acting either in a generic manner or otherwise selective for one or a few specific p53 mutations. In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by targeting these negative regulators with inhibitors. Although the results of at least some clinical trials of MDM2 inhibitors and mutant p53-restoring compounds are promising, none of the agents has yet been approved by the FDA. Alternative strategies, based on a better understanding of p53 biology, the mechanisms of action of compounds and treatment regimens as well as the development of new technologies are gaining interest, such as proteolysis-targeting chimeras for MDM2 degradation. Other approaches are taking advantage of the progress made in immune-based therapies for cancer. In this Review, we present these ongoing clinical trials and emerging approaches to re-evaluate the current state of knowledge of p53-based therapies for cancer.

Census and evaluation of p53 target genes

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Tumor Suppressor P53 and Its Gain-of-function Mutants in Cancer

Gene regulation by the tumor suppressor p53 - The omics era

Differential gene expression in cells with different p53 mutations identifies genome-wide p53 targets and shows distinct modulation of cellular pathways in response to DNA damage

An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Putting p53 in Context

P53 and Its Downstream Proteins As Molecular Targets of Cancer

At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity

Preferential translation of p53 target genes

Tumor Suppressor P53 and Its Mutants in Cancer Metabolism.

Cellular adaptation to hypoxia and p53 transcription regulation

Determinants of p53 DNA binding, gene regulation, and cell fate decisions

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

Progress and Prospects: Roles of P53 in Tumor Development

Regulation of p53 Protein by Transcription Factors

p53 signaling in cancer progression and therapy

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

Translating p53-based therapies for cancer into the clinic